Lung Cancer Panel Kit, tap a thumbnail to see more views.
Lung Cancer Panel Kit
The Lung Cancer Panel from TRUPCR® enables accurate detection of EGFR mutations, PIK3CA mutations, and ALK fusions from FFPE tissue samples using Real-Time PCR. This kit provides a complete solution for laboratories, including reagents, controls, and validated workflows compatible with widely used PCR platforms. With its high sensitivity and specificity, the TRUPCR® Lung Cancer Mutations Panel Kit supports reliable molecular diagnostics, guiding targeted treatment strategies such as EGFR tyrosine kinase inhibitors and ALK inhibitors. Designed for clinical chemists, molecular diagnostics experts, and oncology researchers, this assay ensures confidence in mutation profiling for lung cancer patients.
Quote-based, no public pricing. Add to your quote and our specialists put together a proposal with the right documentation, typically within 24 hours.
This kit in detail
The Lung Cancer Panel from TRUPCR® enables accurate detection of EGFR mutations, PIK3CA mutations, and ALK fusions from FFPE tissue samples using Real-Time PCR. This kit provides a complete solution for laboratories, including reagents, controls, and validated workflows compatible with widely used PCR platforms. With its high sensitivity and specificity, the TRUPCR® Lung Cancer Mutations Panel Kit supports reliable molecular diagnostics, guiding targeted treatment strategies such as EGFR tyrosine kinase inhibitors and ALK inhibitors. Designed for clinical chemists, molecular diagnostics experts, and oncology researchers, this assay ensures confidence in mutation profiling for lung cancer patients.
- Comprehensive Lung Cancer Panel for EGFR, PIK3CA mutations & ALK fusions
- High sensitivity and specificity with clinically relevant targets
- All reagents and controls included – ready-to-use workflow
- Compatible with major Real-Time PCR instruments
What is in the Lung Cancer Panel?
The Lung Cancer Panel is a diagnostic molecular tool that enables the detection of common mutations and fusions linked to lung cancer progression and therapy response. This kit identifies mutations in EGFR (exons 18–21), PIK3CA (exons 7, 9, 20), and fusions in the ALK gene from FFPE tissue samples. These biomarkers are essential in predicting tumor behavior and guiding precision therapies.
Lung cancer remains the leading cause of cancer-related mortality globally, and precise molecular diagnostics are crucial to improve survival outcomes. The TRUPCR® panel consolidates multiple critical targets into one streamlined workflow.
Role of the Targets in Disease
-
EGFR Mutations: Found in exons 18–21, mutations like L858R, T790M, and Ex20ins are associated with responsiveness or resistance to EGFR tyrosine kinase inhibitors.
-
PIK3CA Mutations: Commonly detected in exons 7, 9, and 20, PIK3CA mutations activate the PI3K/AKT signaling pathway, contributing to tumor progression and resistance mechanisms.
-
ALK Fusions: ALK rearrangements result in constitutive kinase activation and uncontrolled growth. Detecting ALK fusions is critical for identifying patients eligible for ALK inhibitor therapies.
Together, these markers form the foundation for personalized treatment decisions in non-small cell lung cancer (NSCLC).
About the TRUPCR® Lung Cancer Mutations Panel Kit
The TRUPCR® kit is designed as an all-in-one molecular diagnostic solution:
-
Targets EGFR, PIK3CA, and ALK with a high degree of accuracy
-
Validated for use with formalin-fixed paraffin-embedded (FFPE) tissue samples
-
Includes all necessary reagents and controls, reducing workflow complexity
-
Compatible with widely adopted PCR systems: Applied Biosystems™, QuantStudio®, Rotor-Gene Q, Bio-Rad CFX96/384, AriaMx, and Roche LightCycler® 480-II
By providing reproducible results, the kit helps clinicians and laboratories deliver actionable data to support patient care.
Principle and Workflow
The TRUPCR® Lung Cancer Panel uses Real-Time PCR to detect mutations and fusions.
-
DNA/RNA Extraction from FFPE tissue
-
Amplification using mutation- and fusion-specific primers
-
Detection via fluorescent probes across multiple channels
-
Result Analysis to identify specific mutation/fusion profiles
This streamlined process ensures rapid turnaround and highly specific results without the need for complex sequencing workflows.
Clinical Application
The TRUPCR® Lung Cancer Panel is essential for:
-
Diagnostic profiling of lung cancer patients
-
Treatment guidance for EGFR-targeted therapies and ALK inhibitors
-
Resistance monitoring for mutations such as EGFR T790M
-
Research applications in oncology and drug resistance
Its high sensitivity enables detection of clinically relevant mutations even in samples with limited DNA/RNA availability, supporting better patient stratification and therapy outcomes.
Datasheets and regulatory documentation
Everything your quality team needs for evaluation and procurement.
Product Catalogus
Frequently paired with this kit
Other assays and instruments lab teams add alongside the Lung Cancer Panel Kit.
Add this kit to your quote
Tell us the platforms and throughput you’re planning for and our specialists will put together a clear proposal with the right documentation, no public pricing, just a considered answer.
